Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
253 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
High-Grade Glioma - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape. Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively. High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology). - The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage High-Grade Glioma - Overview High-Grade Glioma - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes High-Grade Glioma - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type High-Grade Glioma - Companies Involved in Therapeutics Development Advenchen Laboratories LLC AngioChem Inc Arog Pharmaceuticals Inc Astellas Pharma Inc Athenex Inc Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company BTG Plc Cavion LLC CBT Pharmaceuticals Inc Concordia International Corp DelMar Pharmaceuticals Inc Ipsen SA Millennium Pharmaceuticals Inc Nektar Therapeutics Novartis AG Ono Pharmaceutical Co Ltd Sanofi Sorrento Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Targepeutics Inc Tocagen Inc ZIOPHARM Oncology Inc High-Grade Glioma - Drug Profiles AdRTSIL-12 - Drug Profile Product Description Mechanism Of Action R&D Progress afatinib dimaleate - Drug Profile Product Description Mechanism Of Action R&D Progress alisertib - Drug Profile Product Description Mechanism Of Action R&D Progress apatinib - Drug Profile Product Description Mechanism Of Action R&D Progress bendamustine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress BMX-001 - Drug Profile Product Description Mechanism Of Action R&D Progress cabazitaxel - Drug Profile Product Description Mechanism Of Action R&D Progress CBT-101 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Gliomas - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for High-Grade Glioma - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress crenolanib besylate - Drug Profile Product Description Mechanism Of Action R&D Progress CYT-107 - Drug Profile Product Description Mechanism Of Action R&D Progress dabrafenib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile Product Description Mechanism Of Action R&D Progress dianhydrogalactitol - Drug Profile Product Description Mechanism Of Action R&D Progress DSP-7888 - Drug Profile Product Description Mechanism Of Action R&D Progress etirinotecan pegol - Drug Profile Product Description Mechanism Of Action R&D Progress flucytosine + TBio-01 - Drug Profile Product Description Mechanism Of Action R&D Progress flucytosine ER + vocimagene amiretrorepvec - Drug Profile Product Description Mechanism Of Action R&D Progress GB-13 - Drug Profile Product Description Mechanism Of Action R&D Progress HSV-1716 - Drug Profile Product Description Mechanism Of Action R&D Progress ipilimumab + nivolumab - Drug Profile Product Description Mechanism Of Action R&D Progress irinotecan hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress irinotecan hydrochloride + TBio-02 - Drug Profile Product Description Mechanism Of Action R&D Progress irinotecan hydrochloride CR - Drug Profile Product Description Mechanism Of Action R&D Progress KX-02 - Drug Profile Product Description Mechanism Of Action R&D Progress mibefradil dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress nivolumab - Drug Profile R&D Progress Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress paclitaxel trevatide - Drug Profile Product Description Mechanism Of Action R&D Progress porfimer sodium - Drug Profile Product Description Mechanism Of Action R&D Progress RRX-001 - Drug Profile Product Description Mechanism Of Action R&D Progress sorafenib tosylate - Drug Profile Product Description Mechanism Of Action R&D Progress High-Grade Glioma - Dormant Projects High-Grade Glioma - Discontinued Products High-Grade Glioma - Product Development Milestones Featured News & Press Releases May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma May 28, 2015: Cavion to Present Clinical Trial Data at ASCO Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for High-Grade Glioma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1 2017 High-Grade Glioma - Pipeline by AngioChem Inc, H1 2017 High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017 High-Grade Glioma - Pipeline by Astellas Pharma Inc, H1 2017 High-Grade Glioma - Pipeline by Athenex Inc, H1 2017 High-Grade Glioma - Pipeline by Bayer AG, H1 2017 High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 High-Grade Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017 High-Grade Glioma - Pipeline by BTG Plc, H1 2017 High-Grade Glioma - Pipeline by Cavion LLC, H1 2017 High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017 High-Grade Glioma - Pipeline by Concordia International Corp, H1 2017 High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 High-Grade Glioma - Pipeline by Ipsen SA, H1 2017 High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 High-Grade Glioma - Pipeline by Nektar Therapeutics, H1 2017 High-Grade Glioma - Pipeline by Novartis AG, H1 2017 High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 High-Grade Glioma - Pipeline by Sanofi, H1 2017 High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1 2017 High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 High-Grade Glioma - Pipeline by Targepeutics Inc, H1 2017 High-Grade Glioma - Pipeline by Tocagen Inc, H1 2017 High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017 High-Grade Glioma - Dormant Projects, H1 2017 High-Grade Glioma - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
